Functional impairment and disability among patients with migraine: evaluation of galcanezumab in a long-term, open-label study
Sign Up to like & getrecommendations! Published in 2020 at "Quality of Life Research"
DOI: 10.1007/s11136-020-02632-0
Abstract: Migraine can negatively impact patient functioning and quality of life. Here, we report the effects of galcanezumab (GMB), a humanized monoclonal antibody that binds to calcitonin gene-related peptide, on patient-reported outcome (PRO) measures in migraine.… read more here.
Keywords: gmb 240; study; open label; gmb 120 ... See more keywords